By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem - 2Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers
- 3Triumph’s Gorgeous, Super-Affordable and Approachable New Street Motos Share a Heart But Not a Soul
- 4'Everyone in this prison has had family killed or shot'
- 57 Delightful Ferris Wheels, Do You Like Them?
- Obamacare enrollment declines as US subsidies expire
- Germany's Bundestag extends two armed forces missions abroad
- From Representative to Business visionary: Private issue Victories
- German state railway loss widens, passengers warned of trouble ahead
- Fascinating Fishing Objections From Around The World
- Trial of pro-Palestine activist begins
- Collins Foods to offload 20 Taco Bell outlets in Australia
- Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- Before trips to Mars, we need better protection from cosmic rays
